Trial Profile
A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Myasthenia gravis
- Focus Proof of concept; Therapeutic Use
- Sponsors UCB Biopharma
- 11 May 2023 Results of post hoc analysis assessing the newly developed MG Symptoms Patient-Reported Outcome (PRO) instrument complements the available measures of MG severity published in the Neurology and Therapy
- 20 Nov 2020 Results published in the Neurology.
- 18 Oct 2018 According to a UCB media release, full data from this study will be presented at a medical congress in the near future and submitted for publication in a peer-reviewed journal.